Literature DB >> 21543510

Pentazocine-induced antinociception is mediated mainly by μ-opioid receptors and compromised by κ-opioid receptors in mice.

Haihua Shu1, Masakazu Hayashida, Hideko Arita, Wenqi Huang, Hui Zhang, Ke An, Guiyun Wu, Kazuo Hanaoka.   

Abstract

Pentazocine is a widely used mixed agonist-antagonist opioid. Previous animal studies have demonstrated that pentazocine-induced antinociception displayed a ceiling effect characterized by biphasic dose response with a increasing and then descending analgesia like a bell-shaped curve. This study attempted to clarify the mechanisms underlying such dose-response relationships. ddY and C57BL/6J mice received subcutaneous injection of saline or pentazocine (3, 10, 30, 56, or 100 mg · kg(-1)), at 120 min after subcutaneous injection of saline, a μ-opioid receptor antagonist clocinnamox mesylate (C-CAM) (5 mg · kg(-1)), a κ-opioid receptor antagonist nor-binaltorphimine (nor-BNI) (10 mg · kg(-1)), or the combination of C-CAM and nor-BNI. The antinociceptive effects of pentazocine were evaluated using tail pressure, hot plate, tail flick, and acetic acid writhing tests. Without pretreatment with an opioid receptor antagonist, the antinociceptive effects of pentazocine exhibited biphasic bell-shaped dose-response curves peaking at 30 mg · kg(-1). C-CAM completely and partly antagonized the antinociception induced by pentazocine at low (3-30 mg · kg(-1)) and high (56-100 mg · kg(-1)) doses, respectively. nor-BNI enhanced the antinociception by pentazocine at high doses and turned the later descending portion of the biphasic dose-response curves into a sigmoid curve. The combination of C-CAM and nor-BNI completely abolished the antinociception by pentazocine at all doses. Our results suggest pentazocine produces antinociception primarily via activation of μ-opioid receptors, but at high doses, this μ-opioid receptor-mediated antinociception is antagonized by concomitant activation of κ-opioid receptors. This provides the first reasonable hypothesis to explain the ceiling effects of pentazocine analgesia characterized by a biphasic dose response.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21543510     DOI: 10.1124/jpet.111.179879

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  6 in total

1.  Antinociceptive Effects and Interaction Mechanisms of Intrathecal Pentazocine and Neostigmine in Two Different Pain Models in Rats.

Authors:  Huiying Huang; Xiaohui Bai; Kun Zhang; Jin Guo; Shaoyong Wu; Handong Ouyang
Journal:  Pain Res Manag       Date:  2022-05-18       Impact factor: 2.667

2.  Ligand directed signaling differences between rodent and human κ-opioid receptors.

Authors:  Selena S Schattauer; Mayumi Miyatake; Haripriya Shankar; Chad Zietz; Jamie R Levin; Lee-Yuan Liu-Chen; Vsevolod V Gurevich; Mark J Rieder; Charles Chavkin
Journal:  J Biol Chem       Date:  2012-10-19       Impact factor: 5.157

3.  Estrogen facilitates and the kappa and mu opioid receptors mediate antinociception produced by intrathecal (-)-pentazocine in female rats.

Authors:  Douglas L Robinson; Subodh Nag; Sukhbir S Mokha
Journal:  Behav Brain Res       Date:  2016-06-14       Impact factor: 3.332

4.  Increased Hyperalgesia and Proinflammatory Cytokines in the Spinal Cord and Dorsal Root Ganglion After Surgery and/or Fentanyl Administration in Rats.

Authors:  Lu Chang; Fang Ye; Quehua Luo; Yuanxiang Tao; Haihua Shu
Journal:  Anesth Analg       Date:  2018-01       Impact factor: 5.108

5.  Negative modulation of spinal κ-opioid receptor-mediated antinociception by the µ-opioid receptor at selective doses of (-)-pentazocine.

Authors:  Douglas L Robinson; Subodh Nag; Sukhbir S Mokha
Journal:  Neuroreport       Date:  2018-07-04       Impact factor: 1.837

6.  Pharmacological Characterization of Dezocine, a Potent Analgesic Acting as a κ Partial Agonist and μ Partial Agonist.

Authors:  Yu-Hua Wang; Jing-Rui Chai; Xue-Jun Xu; Ru-Feng Ye; Gui-Ying Zan; George Yun-Kun Liu; Jian-Dong Long; Yan Ma; Xiang Huang; Zhi-Chao Xiao; Hu Dong; Yu-Jun Wang
Journal:  Sci Rep       Date:  2018-09-20       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.